Skip to main content
Equibles
PRTA logo

PRTA · Prothena Corp Public Ltd Co

Track PRTA — free

Use PRTA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRTA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.86 -0.22 (-2.42%) At close · Aug 14
Market Cap
$454.85M
Shares
51.34M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-08-06 Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
2026-07-30 Prothena to Report Second Quarter 2026 Financial Results on August 6
2026-05-07 Prothena Reports First Quarter 2026 Financial Results and Business Highlights
2026-04-30 Prothena to Report First Quarter 2026 Financial Results on May 7
2026-04-27 Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
2026-04-10 Prothena Announces Leadership Team Updates
2026-03-21 Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
2026-03-09 Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
2026-02-27 Prothena Announces up to $100 Million Share Repurchase Plan
2026-02-19 Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
2026-02-12 Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
2025-12-12 Prothena Announces Board of Directors Update

Past events

Date Event Type
2026-03-21 ADPD 2026: Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease Presentation
2026-03-11 Citizens Life Sciences Conference Conference
2026-02-19 Prothena Fourth Quarter and Full Year 2025 Financial Results Conference Call Earnings call
2025-12-04 Evercore Healthcare Conference Conference
2025-12-03 Piper Sandler Annual Healthcare Conference Conference
2025-11-10 AHA25: Late-Breaking Presentation of Primary Results from the Phase 2 Coramitug Clinical Trial in ATTR-CM Presentation
2025-09-04 Cantor Global Healthcare Conference Conference
2025-04-01 ADPD 2025: PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment Event
2025-02-20 Prothena Fourth Quarter and Full Year 2024 Financial Results Conference Call Earnings call
2024-09-17 Cantor Global Healthcare Conference Conference
2024-03-12 Leerink Partners Global Biopharma Conference Conference
2024-02-15 Prothena Fourth Quarter and Full Year 2023 Financial Results Conference Call Earnings call
2023-09-11 Morgan Stanley Healthcare Conference Conference
2023-07-17 AAIC 2023 Poster Presentation: PRX005, A Novel Anti-MTBR Tau Humanized Monoclonal Antibody: Results from the Single Ascending Dose Portion of a First-in-Human Double-Blind, Placebo-Controlled, Phase 1 Clinical Trial Presentation
2023-07-17 AAIC 2023 Poster Presentation: Immunological response to dual Aβ/Tau vaccine PRX123 surrogate and effects on brain amyloid plaques in rapidly depositing transgenic animal model Presentation
2023-07-17 AAIC 2023 Poster Presentation: Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ Presentation
2023-06-08 Jefferies Healthcare Conference Conference
2023-05-09 Bank of America Healthcare Conference Conference
2023-03-31 ADPD 2023 Oral Presentation: Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Abeta Protofibrils and Robust Clearance of Pyroglutamate-Modified Abeta Presentation
2023-02-23 Prothena Fourth Quarter and Full Year 2022 Financial Results Conference Call Earnings call
2022-02-17 Prothena Fourth Quarter and Full Year 2021 Financial Results Conference Call Earnings call

Source: https://ir.prothena.com/overview/default.aspx

Key facts CIK 1559053 CUSIP G72800108 13F (30d) 181 filings 177 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)